Coutant F , Agaugue S , Perrin-Cocon L , Andre P , Lotteau V
Why should medical distributors include this sachet in their product range
4 Approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors
Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data
Pfizer said it will no longer pursue a twice-daily version of obesity drug danuglipron after it released topline Phase 2b results on Friday
e116177 Published online:Sep 09, 2022 Article type:Research Article Received:May 12, 2021 Accepted:Aug 15, 2022 How to Cite:Kanani F, Etebari M